Phytopharm Announces its Completion of a Level-I ADR Program and its Intention to List on Nasdaq CAMBRIDGE, U.K., Aug. 18, 2004 (PRIMEZONE) -- Phytopharm plc (LSE:PYM) ("Phytopharm") announces today the establishment of a Level-I American Depositary Receipt (ADR) program and its intention to...

Phytopharm Plc -- Collaboration with OPTIMA (University of Oxford) to Advance the Development of PYM50028 as a Treatment for Dementia Cambridge, U.K., June 23, 2003 (PRIMEZONE) -- Phytopharm plc (LSE:PYM) (Other OTC:PHYOF) announces today that it has entered into an agreement with the Oxford Project to Investigate Memory and Ageing...